ERBB2 and neoplasm: Patients with HER2 overexpression frequently display impaired antioxidant capacity, a condition that may help explain our findings and reinforce the hypothesis of a pro-inflammatory tumor microenvironment driven by HER2-associated signaling pathways [18].